Dataset Information

Delta inulin-based adjuvants promote the generation of polyfunctional CD4⁺ T cell responses and protection against Mycobacterium tuberculosis infection.

ABSTRACT: There is an urgent need for the rational design of safe and effective vaccines to protect against chronic bacterial pathogens such as Mycobacterium tuberculosis. Advax™ is a novel adjuvant based on delta inulin microparticles that enhances immunity with a minimal inflammatory profile and has entered human trials to protect against viral pathogens. In this report we determined if Advax displays broad applicability against important human pathogens by assessing protective immunity against infection with M. tuberculosis. The fusion protein CysVac2, comprising the M. tuberculosis antigens Ag85B (Rv1886c) and CysD (Rv1285) formulated with Advax provided significant protection in the lungs of M. tuberculosis-infected mice. Protection was associated with the generation of CysVac2-specific multifu

SUBMITTER: Counoupas C

PROVIDER: S-EPMC5561132 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Delta inulin-based adjuvants promote the generation of polyfunctional CD4⁺ T cell responses and protection against Mycobacterium tuberculosis infection.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Delta inulin-based adjuvants promote the generation of polyfunctional CD4⁺ T cell responses and protection against Mycobacterium tuberculosis infection.